The paper's earlier Dexcom lot-number brief treated the G7 alert as a supply-chain story, not a generic device scare, and FDA's June 3 recall index keeps that frame current by leaving the May 29 Dexcom notice in the active stack. [1]

Dexcom said two lots of G7 sensors, 1725204004 and 1725069002, had been designated as scrap, stolen before destruction and sold through third parties, including sales traced to Pharmsource, which the company said is not an authorized Dexcom distributor. [2]

The risks differ by lot: 1725204004 may carry a higher skin-infection risk because the sensors may not have been properly sterilized, while 1725069002 may carry a higher risk of no sensor readings because of an elevated internal testing failure rate. [2]

Dexcom said no severe adverse events had been reported, a qualifier that belongs beside the lot-specific warnings because this is not a free-floating claim that every G7 sensor is unsafe. [2]

The reader task is exact and practical: do not use sensors from those two lots, avoid third-party supply-chain shortcuts for a device that sits on skin and guides diabetes decisions, check boxes before insertion, and seek replacements through Dexcom support rather than improvising immediately around the patient-safety warning.

-- NORA WHITFIELD, Chicago